Healthcare leaders underscore the critical role of robust metrics in designing and evaluating patient engagement programs, aiming to improve therapy adherence and outcomes. Executives from Acadia Pharmaceuticals and Servier Pharmaceuticals emphasize defining key performance indicators early, including conversion rates and persistency measures, to ensure program effectiveness and patient support throughout treatment journeys. Concurrently, organizations are expanding mental health research funding, exemplified by the Brain & Behavior Research Foundation's $11.4 million investment in young investigators, reflecting growing attention towards precision psychiatry diagnostics and clinician mental health support.